Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Hematopoietic recovery of ex vivo perfusion culture expanded bone marrow and unexpanded peripheral blood progenitors after myeloablative chemotherapy
Autore:
Engelhardt, M; Douville, J; Behringer, D; Jahne, A; Smith, A; Henschler, R; Lange, W;
Indirizzi:
Univ Freiburg, Med Ctr, Div Hematol Oncol, D-79106 Freiburg, Germany Univ Freiburg Freiburg Germany D-79106 Oncol, D-79106 Freiburg, Germany Aastrom Biosci, Ann Arbor, MI USA Aastrom Biosci Ann Arbor MI USAAastrom Biosci, Ann Arbor, MI USA
Titolo Testata:
BONE MARROW TRANSPLANTATION
fascicolo: 3, volume: 27, anno: 2001,
pagine: 249 - 259
SICI:
0268-3369(200102)27:3<249:HROEVP>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
BREAST-CANCER PATIENTS; STEM-CELL TRANSPLANTATION; HIGH-DOSE CHEMOTHERAPY; IMMUNODEFICIENT MICE; TELOMERASE ACTIVITY; LYMPHOMA PATIENTS; SELF-RENEWAL; CORD-BLOOD; EXPANSION; PROLIFERATION;
Keywords:
ex vivo culture; autologous transplantation; STAMP V;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
44
Recensione:
Indirizzi per estratti:
Indirizzo: Engelhardt, M Univ Freiburg, Med Ctr, Div Hematol Oncol, Hugstetter Str 55, D-79106 Freiburg, Germany Univ Freiburg Hugstetter Str 55 Freiburg Germany D-79106 ny
Citazione:
M. Engelhardt et al., "Hematopoietic recovery of ex vivo perfusion culture expanded bone marrow and unexpanded peripheral blood progenitors after myeloablative chemotherapy", BONE MAR TR, 27(3), 2001, pp. 249-259

Abstract

Ex vivo culture of hematopoietic progenitor cells for autologous transplantation has generated world-wide interest, since it offers the prospect of using a limited cell number, and may allow more efficient gene transfer and passive elimination of contaminating tumor cells, In this study, we expanded bone marrow (BM) cells from 10 breast cancer patients to determine whether small BM aliquots can durably restore hematopoiesis, and whether thrombopoietin (TPO) improves hematopoietic reconstitution after myeloablative chemotherapy. We used the AastromReplicell System (ARS), performing a computer-controlled, stromal-based cell expansion process with frequent medium, cytokine and gas exchange, For the inoculation of 9x10(8) MNC, a median BM volume of 97.8 ml (range, 72.4-272) was harvested. We found a median 4.5-fold nucleated cell expansion, an 18-fold CFU-GM expansion, and 69% of input LTC-IC numbers, Nucleated and Lin(-)/CD34(+) cells were infused with a median of 43.5 x 10(6)/kg (range, 34.1-71.7) and 2.8 x 10(5)/kg (range, 0.95-5.9), respectively, Despite tumor cell detection by immunocytochemical staining in 3/10 patients before expansion, tumor cells were not detectable in 9/10, and in one patient 1 log reduced post ARS culture. Following high-dose STAMP V chemotherapy, all patients received 12-day expanded BM cells, The median time to engraftment was 17 days (range, 11-20) for WBC >1000/mul, and 28 days (range, 21-55) for platelets >20 000/mul. A correlation between post-expansion Lin(-)/CD34(+) cells and engraftment for ANC >500/mul, WBC >1000/mul and platelets >20 000/mul was observed. Hematopoiesis has been maintained for a median of 15 (range, 6-24) months. Our results demonstrate that transplantation of ex vivo expanded small BM aliquots allows hematopoietic reconstitution after myeloablative chemotherapy. Ex vivo generated ARS cells can reduce the risk of tumor cell reinoculation with autotransplants and maybe valuable in settings in which only small stem cell doses are available,eg when using cord blood transplants or in non-mobilizing patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 17:50:07